People with Down syndrome are likely to develop Alzheimer’s disease at a young age, with autopsy studies showing that by age 40 years, the brains of individuals with Down syndrome have amyloid plaques. Yet people with Down syndrome have been excluded from or underrepresented in clinical trials of new therapies for treating AD. Lecanemab, which has been shown to target and remove beta-amyloid plaques, has been approved by the U.S. Food and Drug Administration to treat AD early in the disease’s progression.
Medical Xpress – latest medical and health news stories
